These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 27654169)

  • 1. A conjugate of methotrexate and an analog of luteinizing hormone releasing hormone shows increased efficacy against prostate cancer.
    Zhu S; Wang Q; Jiang J; Luo Y; Sun Z
    Sci Rep; 2016 Sep; 6():33894. PubMed ID: 27654169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [DLys(6)]-luteinizing hormone releasing hormone-curcumin conjugate inhibits pancreatic cancer cell growth in vitro and in vivo.
    Aggarwal S; Ndinguri MW; Solipuram R; Wakamatsu N; Hammer RP; Ingram D; Hansel W
    Int J Cancer; 2011 Oct; 129(7):1611-23. PubMed ID: 21484797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The in vivo antitumor activity of LHRH targeted methotrexate-human serum albumin nanoparticles in 4T1 tumor-bearing Balb/c mice.
    Taheri A; Dinarvand R; Ahadi F; Khorramizadeh MR; Atyabi F
    Int J Pharm; 2012 Jul; 431(1-2):183-9. PubMed ID: 22531853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors.
    Leuschner C; Enright FM; Gawronska-Kozak B; Hansel W
    Prostate; 2003 Sep; 56(4):239-49. PubMed ID: 12858351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of methotrexate-monoclonal anti-prostatic acid phosphatase antibody conjugate on human prostate tumor.
    Deguchi T; Chu TM; Leong SS; Horoszewicz JS; Lee CL
    Cancer Res; 1986 Aug; 46(8):3751-5. PubMed ID: 3731053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels.
    Popovics P; Schally AV; Szalontay L; Block NL; Rick FG
    Oncotarget; 2014 Jun; 5(12):4567-78. PubMed ID: 24994120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
    Engel J; Emons G; Pinski J; Schally AV
    Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
    Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
    Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced anti-tumoral activity of methotrexate-human serum albumin conjugated nanoparticles by targeting with Luteinizing Hormone-Releasing Hormone (LHRH) peptide.
    Taheri A; Dinarvand R; Atyabi F; Ahadi F; Nouri FS; Ghahremani MH; Ostad SN; Borougeni AT; Mansoori P
    Int J Mol Sci; 2011; 12(7):4591-608. PubMed ID: 21845098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of LHRH agonists on the growth of human prostatic tumor cells: "in vitro" and "in vivo" studies.
    Montagnani Marelli M; Moretti RM; Dondi D; Limonta P; Motta M
    Arch Ital Urol Androl; 1997 Sep; 69(4):257-63. PubMed ID: 9396187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
    Bajo AM; Schally AV; Halmos G; Nagy A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3742-8. PubMed ID: 14506166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor apoptosis induced by epoxide-containing piperazines, a new class of anti-cancer agents.
    Eilon GF; Gu J; Slater LM; Hara K; Jacobs JW
    Cancer Chemother Pharmacol; 2000; 45(3):183-91. PubMed ID: 10663635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop.
    Dondi D; Limonta P; Moretti RM; Marelli MM; Garattini E; Motta M
    Cancer Res; 1994 Aug; 54(15):4091-5. PubMed ID: 8033142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway.
    Limonta P; Moretti RM; Marelli MM; Dondi D; Parenti M; Motta M
    Endocrinology; 1999 Nov; 140(11):5250-6. PubMed ID: 10537155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling.
    Wells A; Souto JC; Solava J; Kassis J; Bailey KJ; Turner T
    Clin Cancer Res; 2002 Apr; 8(4):1251-7. PubMed ID: 11948140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP.
    Limonta P; Dondi D; Moretti RM; Maggi R; Motta M
    J Clin Endocrinol Metab; 1992 Jul; 75(1):207-12. PubMed ID: 1320049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
    Engel JB; Keller G; Schally AV; Nagy A; Chism DD; Halmos G
    Fertil Steril; 2005 Apr; 83 Suppl 1():1125-33. PubMed ID: 15831285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue.
    Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Westphal G; Halmos G; Engel JB
    Cancer Res; 2005 Jul; 65(13):5857-63. PubMed ID: 15994963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased incidence of luteinizing hormone-releasing hormone receptor gene messenger RNA expression in hormone-refractory human prostate cancers.
    Straub B; Müller M; Krause H; Schrader M; Goessl C; Heicappell R; Miller K
    Clin Cancer Res; 2001 Aug; 7(8):2340-3. PubMed ID: 11489810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
    Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Halmos G; Engel JB
    Clin Cancer Res; 2005 Aug; 11(15):5549-57. PubMed ID: 16061872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.